Search Results (124)

Propolis produced by honeybees, Apis mellifera, has been valued since ancient times as a remedy for different ailments for its broad medicinal properties. This wide range of biological activities may arise from the production of distinct propolis types within the hive, each serving specific functions and containing unique molecular compositions. In this study, we investigated the effects of four propolis types—masonry, sealing, brood-protection, and intruder-neutralizing—on hydrogen peroxide (H₂O₂)-induced oxidative injury in human skeletal muscle cells. Among these, only brood-protection propolis significantly prevented the H₂O₂-induced loss of cell viability. Bio-guided fractionation of this active propolis identified five major compounds: benzyl caffeate (BC), caffeic acid phenethyl ester (CAPE), cinnamyl caffeate (CC), prenyl caffeate (PC), and (E)-3-methyl-3-butenyl caffeate (MBC), all displaying stronger cytoprotective effects than their ferulate equivalents. We finally demonstrated that propolis extract and its active compounds reduced lipid peroxidation in post-mortem minced mouse skeletal muscle and compared their efficacy to other natural compounds. Chemical analysis of resins from neighboring flora suggested that black poplar (Populus nigra) buds are the primary botanical source of these caffeate derivatives. Collectively, these results highlight the functional diversity of hive propolis and its potential applications in food preservation as well as in complementary and preventive medicine. Full article

Background: Aberrant signalling through the urokinase-type plasminogen activator receptor (uPAR) is a key driver of tumour invasion and progression in prostate cancer, yet linking molecular-level perturbations to emergent spatial invasion phenotypes remains challenging. Methods: In this study, we developed a multiscale in silico framework combining molecular docking, mechanistic ordinary differential equation (ODE) modelling, and agent-based modelling (ABM) to investigate uPAR-driven invasion dynamics. Results: Molecular docking and MM-GBSA analyses were used to prioritise caffeic acid phenethyl ester (CAPE) as a candidate uPA/uPAR modulator, while uPAR inhibition was implemented mechanistically at the signalling level within the ODE model rather than through direct energetic parametrisation. Steady-state signalling outputs were mapped to effective proliferation and motility rates, which served as inputs to a spatial ABM of tumour invasion. The integrated simulations showed that uPAR inhibition results in statistically significant reductions in spatial invasion and tumour growth compared with baseline conditions, whereas enhanced uPA signalling produced only modest, non-significant trends. Conclusions: These findings demonstrate how subtle intracellular signalling perturbations can translate into pronounced population-level invasion phenotypes when embedded in a spatial context. Overall, the proposed digital-twin framework provides a coherent and extensible approach for connecting molecular prioritisation with quantitative predictions of tumour invasion behaviour in prostate cancer. Full article

(1) Background: Caffeic acid phenethyl ester (CAPE) exhibits anticancer activity; however, its time-dependent effects on interconnected signalling pathways remain incompletely characterised. (2) Methods: We combined wet-lab experiments (MTT viability assay and ELISA measurements of total $NF-\kappa B$ p65 and p53) with a Bayesian digital twin framework to quantify signalling dynamics in prostate cancer cells following CAPE exposure. p53-deficient PC3 and p53-competent LNCaP cell lines were treated for 24 h and 48 h across multiple CAPE concentrations. Experimental data were integrated into a mechanistic Bayesian model using robust likelihoods, enabling uncertainty-aware parameter inference and posterior predictive validation via leave-one-dose-out analysis. (3) Results: In PC3 cells, CAPE induced dose-dependent inhibition of $NF-\kappa B$ p65 that was consistently associated with reduced cell viability at both time points, consistent with a p53-independent regulatory regime. In contrast, LNCaP cells exhibited a transient $NF-\kappa B$–p53 coupling at 24 h, characterised by delayed $NF-\kappa B$ suppression and pronounced p53 activation, followed by a more stable and weakly coupled signalling state at 48 h. These temporal patterns were supported by posterior parameter estimates and predictive performance under leave-one-dose-out validation. (4) Conclusions: This study demonstrates that Bayesian digital twins enable quantitative, uncertainty-aware analysis of time-dependent drug responses, extending beyond conventional dose–response assessments and supporting mechanistic hypothesis generation in cancer pharmacology. Full article

Propolis is a rich natural source of biologically active polyphenols; however, their therapeutic potential is often limited by poor oral bioaccessibility and bioavailability. This study reports the development and validation of a high-performance liquid chromatography–diode array detector (HPLC–DAD) method optimized for the quantification of major propolis polyphenols—caffeic acid (CA), pinocembrin (PC), chrysin (CR), caffeic acid phenethyl ester (CAPE), and galangin (GN) in 2-hydroxypropyl-β-cyclodextrin (HP-β-CD)-based complexes. A green complexation approach based on HP-β-CD and lyophilization was applied to continental propolis, yielding a water-soluble formulation suitable for oral administration. The isocratic HPLC–DAD method demonstrated linearity, sensitivity, and precision, suitable for reliable analysis of polyphneols in cyclodextrin-based matrices. Gastrointestinal behavior was evaluated using a simulated oral, gastric, and intestinal digestion model. PC and CAPE remained stable throughout digestion, whereas GN, CR, and CA showed higher sensitivity, with decreases of 43.1–71.6% compared to undigested samples. HP-β-CD complexation enhanced polyphenol solubility and improved gastrointestinal stability. Intestinal bioaccessibility, assessed by a centrifugation model, ranged from 77.2% (CR) to 124.9% (CA). However, the complexes did not permeate the artificial intestinal membrane, resulting in reduced dialyzable polyphenols, with CA being undetectable. These findings provide a validated analytical platform and mechanistic insight into the gastrointestinal behavior of cyclodextrin-complexed propolis polyphenols, supporting their application in oral functional formulations. Full article

The glioblastoma multiforme (GBM) microenvironment, characterized by hypoxia and inflammation, is a principal driver of therapeutic resistance. Although natural compounds such as Caffeic Acid Phenethyl Ester (CAPE) are investigated for their anti-neoplastic properties, their bioactivity within the distinct metabolic landscape of the tumor core remains to be fully elucidated. Taking advantage of the recognized immunomodulatory properties of CAPE and its ability to cross the blood–brain barrier, we hypothesized that hypoxia is a key factor determining its effect on glioma-associated inflammation. To test this hypothesis, we investigated the immunomodulatory effects of CAPE on the human astrocytoma cell line CCF-STTG1. Cells were cultured under normoxic and hypoxic conditions, stimulated with lipopolysaccharide (LPS) and interferon-alpha (IFN-α) to induce an inflammatory phenotype, and subsequently treated with CAPE. The secretion profiles of key cytokines (IL-8, IL-10, IL-26) and matrix metalloproteinases (MMPs) as well as pentraxin-3 (PTX-3) were then quantified using a multiplex immunoassay. Our results revealed a striking functional dichotomy. Under normoxic conditions, CAPE suppressed the secretion of key pro-inflammatory mediators. Conversely, under hypoxic conditions, CAPE significantly amplified the release of pro-tumorigenic factors, including the mediator facilitating tumor cell migration, invasion, and angiogenesis such as IL-8 and the invasion-associated metalloproteinase MMP-2. These findings suggesting that hypoxia may fundamentally reprograms the immunomodulatory potential of CAPE. However, due to limitations of study requires further validation in a broader panel of glioblastoma models. Full article

Background: In this study, 28 caffeic acid phenethyl ester (CAPE) derivatives were designed and synthesized, and their anti-proliferative activities were evaluated against two representative human hepatocellular carcinoma (HCC) cell lines. The half-maximal inhibitory concentration (IC₅₀) was used as the activity metric. Among these derivatives, compound WX006 displayed the most potent anti-proliferative effect, with IC₅₀ values of 3.332 μM and 3.764 μM after 48 h of treatment, significantly lower than those of the parent compound CAPE. Consequently, WX006 was selected for further investigation into its antitumor efficacy and underlying mechanisms. Methods: To investigate the pharmacological mechanism of WX006, we employed a combination of high-throughput transcriptomics, metabolomics, and mitochondrial function analysis to elucidate its intracellular mechanisms of action. Results: WX006 disrupts cytoplasmic-mitochondrial metal ion homeostasis, triggering ferroptosis and cuproptosis through iron-copper dysregulation. Computational modeling revealed that WX006 selectively inhibits mitochondrial NDUFS2 subunit of respiratory chain complex I, which may induce NAD⁺ exhaustion and consequent energy metabolism collapse in tumor cells. These “metabolism & metal homeostasis” dual mechanisms collectively underpin its robust anti-tumor effects. Therapeutic efficacy of WX006 was further validated in murine H22 ectopic xenograft and Hepa1-6-Luc orthotopic xenograft models, where WX006 exhibited superior tumor suppression compared to sorafenib, alongside favorable safety profiles. Conclusions: Our findings establish a foundational rationale for further pharmaceutical development of CAPE derivates as a promising therapeutic candidate for hepatocellular carcinoma. Full article

Background: Malignant ovarian tumours are most often detected at an advanced stage, when peritoneal dissemination across abdominal organs is already present. Metastasis in ovarian cancer arises from complex interactions between cancer cells and diverse components of the tumour microenvironment (TME), including extracellular matrix elements, fibroblasts, adipocytes, mesenchymal cells and leukocytes. This dynamic niche drives tumour progression, invasiveness and immunosuppression through cytokine- and chemokine-mediated signalling. A deeper understanding of these interactions may enable targeted modulation of the TME and help limit metastatic spread. Methods: In this study, using immunoenzymatic assays and a computational digital twin—a mechanistic, ODE-based in silico model that replicates key cellular and microenvironmental processes—we investigated whether and how caffeic acid phenethyl ester (CAPE) influences TME activation, cytokine and growth factor levels, and extracellular matrix remodelling. Results: Our findings show that CAPE modulates both pro- and antitumourigenic signalling pathways across immune, stromal and hypoxia-related axes, suggesting its potential to reshape the ovarian cancer microenvironment and improve therapeutic outcomes in this challenging malignancy. Conclusions: Taken together, these results indicate that CAPE may serve as a multifaceted modulator capable of simultaneously targeting tumour cells and their microenvironment, offering a promising avenue for enhancing therapeutic strategies in ovarian cancer. Full article

Objectives: Bone defects, resulting from many causes, represent a challenge in maxillofacial and orthopedic surgery. Regenerative medicine offers promising strategies by introducing exogenous materials to modify the tissue environment and modulate the body’s natural healing mechanisms. Dental pulp stem cells (DPSCs) are considered an effective source for tissue repair. Small molecules such as caffeic acid phenethyl ester (CAPE), although having promising effects in promoting bone regeneration, are characterized by low chemical stability, which impairs their clinical application. This study aimed to investigate the bone regenerative capability of four CAPE derivatives, recently synthesized in our laboratory and selected based on previous studies. Methods: DPSCs were induced to osteogenic differentiation in the presence of these compounds (0–5 μM), and cell viability, matrix deposition, alkaline phosphatase activity, and osteogenic marker gene expression were evaluated. In addition, bone biomaterials composed of a chitosan/agarose matrix reinforced with nanohydroxyapatite and enriched with these CAPE derivatives were fabricated and assessed for cytotoxicity and cell adhesion. Results: Two of the tested compounds effectively enhanced DPSC differentiation toward the osteogenic lineage. The fabricated bone biomaterials showed no cytotoxicity and supported cell adhesion. Furthermore, these compounds demonstrated stability under various conditions, confirming their suitability for incorporation into bone biomaterials. Conclusions: The tested CAPE derivatives exhibit promising osteoinductive properties and stability, offering a valid alternative to traditional therapeutic strategies in regenerative medicine. Full article

Caffeic acid phenethyl ester (CAPE), a polyphenol from propolis, is well recognized for its anti-inflammatory, antioxidant, antimicrobial, and osteogenic properties. This study aimed to develop macroporous bone scaffolds composed of a chitosan/agarose matrix reinforced with nanohydroxyapatite and enriched with stable CAPE derivatives to enhance their biomedical potential for applications in bone tissue engineering and regenerative medicine. A comprehensive evaluation of microstructural and biological properties of the produced scaffolds was conducted. The fabricated scaffolds exhibited high porosity (49–60%) with interconnected pores and compressive strength (1.2–1.8 MPa), closely resembling cancellous bone and indicating suitability for bone regeneration. They were biocompatible, promoted osteoblast adhesion, proliferation, and differentiation, and supported apatite deposition on their surfaces, demonstrating strong bioactivity and potential for implant osseointegration. Importantly, the scaffolds did not trigger excessive production of reactive oxygen or nitrogen species, suggesting a low risk of inflammatory responses. Additionally, CAPE-enriched scaffolds inhibited biofilm formation by Staphylococcus aureus and Staphylococcus epidermidis, reducing the risk of implant-associated infections. In summary, these CAPE-modified scaffolds integrate optimal microstructural and biological features, such as reducing oxidative stress and inhibiting biofilm formation, and thus offer a promising strategy for enhancing bone repair and regeneration in clinical applications. Full article

Osteoarthritis (OA) is a chronic degenerative joint disease with a significant impact on quality of life. This review summarizes recent advances in the understanding of OA pathophysiology, emphasizing mechanical factors, angiogenesis, aging, and the role of interleukins in disease progression. It also explores key molecular pathways, particularly the NF-κB signaling cascade, and crucial catabolic mediators such as MMPs and ADAMTS, which are involved in cartilage degradation. Emerging therapeutic strategies are discussed, with a focus on the potential of polyphenols, such as pinocembrin and caffeic acid phenethyl ester, in cartilage protection and regeneration. In addition, nanotechnology is examined as a promising tool to enhance the bioavailability of these bioactive compounds and support the development of innovative OA treatments. Drug delivery systems based on nanotechnology, including porous silicon nanoparticles functionalized with β-cyclodextrin, have shown promise in improving therapeutic efficacy. This review highlights the importance of multidisciplinary approaches integrating molecular biology, natural compounds, and advanced technologies in the treatment of OA. Full article

Background and Objectives: Alzheimer’s disease (AD) is a complex neurodegenerative disorder marked by cholinergic deficits, oxidative stress, amyloid-β (Aβ) aggregation, and tau hyperphosphorylation. Caffeic acid (CA), a naturally occurring hydroxycinnamic acid, has emerged as a promising neuroprotective candidate due to its antioxidant, anti-inflammatory, and enzyme-inhibitory properties. This review systematically evaluates recent in vitro and in vivo evidence regarding the therapeutic potential of CA in AD models and examines the impact of delivery systems and derivatives on its efficacy and bioavailability. Materials and Methods: A systematic literature search was conducted in the PubMed, Scopus, and Web of Science databases, adhering to the PRISMA 2020 guidelines. Studies published between January 2021 and April 2025 were included in this review. Eligible studies investigated the effects of CA or CA-enriched extracts on AD-relevant mechanisms using in vitro, in vivo, and in silico models. After screening 101 articles, 44 met the inclusion criteria and were included in the final qualitative synthesis of the study. Results: In vitro studies have confirmed that CA modulates cholinergic activity by inhibiting AChE and BChE and exerting antioxidant and anti-amyloidogenic effects. In vivo studies using pharmacological, genetic, and metabolic AD models have demonstrated improvements in cognitive function, reduction in oxidative stress, inflammation, and Aβ and tau pathologies following CA administration. Advanced delivery platforms, such as solid lipid nanoparticles, transferrin-functionalized liposomes, and carbon dot systems, have significantly enhanced CA’s brain bioavailability and therapeutic efficacy. CA derivatives, including caffeic acid phenethyl ester and nitro-substituted analogs, exhibit improved pharmacokinetic and neuroprotective profiles. Conclusions: This review provides evidence supporting the use of CA as a promising multitarget agent against AD pathology. Its therapeutic potential is further enhanced by nanotechnology-based delivery systems and chemical modifications that overcome the limitations of bioavailability. Continued preclinical evaluation and translational studies are warranted to support its clinical development as an AD intervention. Full article

Caffeic acid phenethyl ester (CAPE) is identified to be an efficacious bioactive polyphenol in propolis for ameliorating glucose and lipid metabolism disorders and inflammation. In this study, an alcohol-induced zebrafish inflammation model was established. CAPE treatments at different concentrations (0.04, 0.2, and 1.0 μg/mL) were administered to alcohol-exposed zebrafish to investigate the underlying mechanisms of alleviating alcohol-induced liver inflammation using transcriptomic analysis and 16S rRNA gene sequencing methods. The results indicated that CAPE decreased the expressions of TNF-α and IL-1β and significantly increased the expression of IL-10 (p < 0.0001). Based on the KEGG enrichment analysis of transcriptomic sequencing, CAPE effectively alleviated the inflammation in zebrafish mainly through pancreatic secretion, complement and coagulation cascades, and protein digestion and absorption. Molecular docking supported the potential of CAPE in targeting cholecystokinin (CCK) A Receptor (CCKAR) and mediating the regulation of pancreatic secretion and related inflammation pathways. Moreover, intestinal microbiota analysis demonstrated that CAPE could improve the alcohol-induced microbiota disorder. Additionally, there was a significant correlation between the key genes related to lipid and sterol metabolism among the KEGG-enriched pathways and the specific intestinal microbial communities in zebrafish. Flavobacterium from Bacteroidota was significantly positively correlated with CEL1, CEL2, and LPIN (p < 0.01), which suggested that the anti-inflammatory function of CAPE was closely associated with the intestinal microbiota improvement. In conclusion, our findings demonstrated that CAPE could ameliorate liver inflammation in alcohol-induced zebrafish, which was mainly associated with the regulation of pancreatic secretion and intestinal microbiota disorder. This study emphasized the anti-inflammatory mechanisms of CAPE based on targeting the pancreatic secretion pathway, which will broaden the application of natural antioxidants in improving metabolic and inflammatory problems. Full article

Histone deacetylase 11 (HDAC11), the sole member of class IV HDACs, has gained prominence due to its unique enzymatic profile and pathological relevance in cancer, neurodegenerative, inflammatory diseases, and metabolic disorders. However, only a limited number of selective HDAC11 inhibitors have been identified, and many of these contain a potentially mutagenic hydroxamic acid as a zinc-chelating motif. Consequently, there is an imperative to identify potent and selective non-hydroxamate HDAC11 inhibitors with improved physicochemical properties. In this study, we conducted an extensive experimental high-throughput screening of 10,281 structurally diverse compounds to identify novel HDAC11 inhibitors. Two promising candidates, caffeic acid phenethyl ester (CAPE) and compound 9SPC045H03, both lacking a hydroxamic acid warhead, were discovered, showing micromolar inhibitory potency (IC₅₀ = 1.5 and 2.3 µM, respectively), fast and reversible binding, and remarkable isozyme selectivity. Molecular docking revealed distinct zinc-chelating mechanisms involving either carbonyl oxygen (CAPE) or pyridine nitrogen (9SPC045H03), in contrast to canonical hydroxamates. Both compounds are drug-like and exhibit favorable physicochemical and pharmacokinetic profiles, particularly beneficial water solubility and good adsorption, making them valuable starting points for further optimization. These findings open new avenues for the development of selective, non-hydroxamate HDAC11 inhibitors with potential therapeutic applications. Full article

Purpose: Doxorubicin (DOX) is a broad-spectrum anti-tumor anthracycline drug. However, its clinical application is greatly limited due to the side effect of cardiotoxicity. Caffeic acid phenethyl ester (CAPE) is one of the major biologically active compounds isolated from propolis, which is effective in the treatment of cardiovascular diseases. The purpose of this study aimed to explore the possible mechanism of CAPE’s protective effect on DOX-induced cardiotoxicity (DIC). Methods: In vivo, a DIC model was established by the intraperitoneal injection of 3 mg/kg DOX. The cardiac function of mice was monitored by electrocardiograms. Histopathological changes in myocardial tissue were detected by H&E staining. Serum samples were tested for the level of markers of myocardial injury. In vitro, transmission electron microscopy was used to assess the mitochondrial damage. Oxidative stress was measured by flow cytometry and mitochondrial respiration analysis. Necroptosis pathway changes were detected by Western blotting. Furthermore, the overexpression plasmid of a key necroptosis gene, necroptosis inhibitor or ROS inducer/inhibitor was applied to H9c2 and AC16 cells to explore whether CAPE exerted a protective effect against DIC through the cross-talk mediated by ROS and MLKL. Results: CAPE could improve the cardiac function and protect against myocardial tissue. CAPE pre-administration treatment attenuated the DOX-induced generation of ROS, protected mitochondrial functions and inhibited necroptosis. Moreover, there was cross-talk between the ROS and necroptosis. CAPE could protect against DIC by inhibiting the ROS-MLKL signaling that regulated the cross-talk. Conclusions: CAPE alleviated the oxidative stress and necroptosis of DIC, indicating that the cross-talk mediated by ROS-MLKL signaling may be a potential therapeutic mechanism for clinical DIC. Full article

Caffeic acid phenethyl ester (CAPE) is a polyphenol produced by many plants and is found in red and green propolis. Here, we evaluated the antileishmanial activity of this natural product against Leishmania amazonensis. CAPE exhibited IC₅₀ values of 8.07 µM (95% CI, 6.79–9.62 µM) and 13.51 µM (95% CI, 10.71–17.16 µM) against L. amazonensis promastigotes and intracellular amastigotes, respectively. Additionally, CAPE inhibited L. amazonensis arginase in a non-competitive manner with a K_i value of 1.51 ± 0.04 µM. These results highlight the potential of CAPE as a promising lead compound for developing new therapies against leishmaniasis. Full article